after surgery (hysterectomy and bilateral salpingooophorectomy, Patients with a histological diagnosis of p53abn HREC, treated with curative intent, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
Conditions
Brief summary
Recurrence free survival (RFS) in patients with p53abn EC, as assessed by the investigator. RFS is defined as time from randomization until date of any recurrence (local or distant) or date of death due to any cause
Detailed description
Overall survival (OS) ,Disease-specific survival , Vaginal recurrence-free survival , Pelvic recurrence-free survival , Distant recurrence-free survival
Interventions
DRUGLynparza 100 mg film-coated tablets
DRUGLynparza 150 mg film-coated tablets
Sponsors
Institut Gustave Roussy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival (RFS) in patients with p53abn EC, as assessed by the investigator. RFS is defined as time from randomization until date of any recurrence (local or distant) or date of death due to any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) ,Disease-specific survival , Vaginal recurrence-free survival , Pelvic recurrence-free survival , Distant recurrence-free survival | — |
Countries
France
Outcome results
None listed